Alnylam Discusses RNAi Delivery - - BioPharm International

ADVERTISEMENT

Alnylam Discusses RNAi Delivery



Alnylam Pharmcaeuticals, a company specializing in RNA-interference therapeutics, talks to BioPharm International's Amy Ritter about its RNAi delivery system and its early-stage clinical pipeline.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here